Wellington Management Group LLP Buys 8,001 Shares of Altimmune, Inc. (NASDAQ:ALT)

Wellington Management Group LLP raised its stake in shares of Altimmune, Inc. (NASDAQ:ALT) by 4.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 205,233 shares of the company’s stock after buying an additional 8,001 shares during the quarter. Wellington Management Group LLP owned about 0.29% of Altimmune worth $1,480,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new position in shares of Altimmune in the 3rd quarter worth about $674,000. Barclays PLC increased its stake in Altimmune by 93.0% during the 3rd quarter. Barclays PLC now owns 155,741 shares of the company’s stock valued at $956,000 after purchasing an additional 75,064 shares in the last quarter. Geode Capital Management LLC raised its holdings in Altimmune by 4.7% in the third quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock worth $10,244,000 after buying an additional 74,194 shares during the last quarter. FMR LLC lifted its stake in shares of Altimmune by 546.8% in the third quarter. FMR LLC now owns 51,060 shares of the company’s stock worth $314,000 after buying an additional 43,166 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Altimmune by 318.6% during the third quarter. BNP Paribas Financial Markets now owns 42,140 shares of the company’s stock valued at $259,000 after buying an additional 32,072 shares during the last quarter. 78.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Gregory L. Weaver acquired 10,000 shares of Altimmune stock in a transaction dated Thursday, March 13th. The stock was purchased at an average cost of $5.20 per share, with a total value of $52,000.00. Following the completion of the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at approximately $52,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.10% of the company’s stock.

Altimmune Stock Up 6.0 %

NASDAQ ALT opened at $4.41 on Monday. The firm has a market capitalization of $339.63 million, a P/E ratio of -2.85 and a beta of 0.91. The company has a 50-day moving average price of $5.62 and a 200-day moving average price of $6.80. Altimmune, Inc. has a 52 week low of $3.55 and a 52 week high of $11.16.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. As a group, equities research analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ALT shares. Stifel Nicolaus assumed coverage on shares of Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, April 3rd. Finally, William Blair reaffirmed a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Altimmune presently has an average rating of “Moderate Buy” and an average target price of $20.83.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.